This preclinical study explains the mechanism underlying CDK2 and CDK4/6 combination therapy, providing a blueprint for future clinical use These findings are notable because several CDK2 inhibitor ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced ...
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results